mykeystrokes.com

"Do or Do not. There is no try."

Eric Cantor Loves Government Spending…On The Drug Industry

Republicans would like you to believe that our deficit problem is primarily a spending problem and that responsibility for that problematic spending is primarily a Democratic responsibility. But the second claim is as misleading as the first. Republicans have also been known to promote wasteful government spending, particularly when it goes towards an industry with which they happen to be cozy. For a vivid illustration of this, look no further than a new Politico article about House Majority Leader Eric Cantor and his position on a key deficit reduction proposal.

The proposal in question would lower the cost of what the federal government currently pays to provide low-income seniors with prescription drugs. For years, the government purchased drugs for these seniors directly through Medicaid, taking advantage of the low prices drug companies must, by law, provide when selling drugs for the people in that program. But that changed in 2006, with the creation of Medicare drug benefit. At that point, the government delegated the purchasing of drugs for low-income seniors to private firms. And the firms haven’t been able to negotiate equally deep discounts, partly because of restrictions on their ability to limit drug availability.

According to the Congressional Budget Office, restoring the “Medicaid discount” for low-income seniors could save more than $100 billion over the course of a decade, depending on the structure of the proposal. And, at one point, many health care reformers had hoped to include that proposal as part of what became the Affordable Care Act. The administration and leaders of the Senate Finance Committee agreed not to include the proposal in the final legislation, as part of their infamous deal with the drug industry lobby. But that was a one-time deal, at least in theory, and congressional negotiators are looking seriously at enacting the proposal now.

The problem is lawmakers like Cantor, who oppose the idea. According to the Politico story, written by Matt Dobias, Cantor is making the same argument that the drug industry lobby does: That the proposal would amount to a form of government price controls, retarding economic growth and discouraging innovation.

The latter point is highly dubious: The reduction would bring reimbursement levels for these drugs very close to what they were a few years ago. Many experts, including the CBO, think the likely impact on research and development would be negligible. (Harvard economists Richard Frank and Joseph Newhouse addressed this issue at some length in Health Affairs a few years ago.)

As for the former suggestion, it’s true that any net reduction in government spending could reduce economic growth, at least at this particular moment. That’s why it’s not a good idea to be madly slashing government spending right now — and why, perhaps, congressional negotiators should delay implementation of this cut, like the others, so that it would take effect after the economy has more fully recovered.

But Cantor’s anxiety over the economic ramifications of spending cuts seems strangely selective. He hasn’t raised similar concerns about cuts to food stamps, Medicaid, and similar programs that would likely have a more devastating impact, both on the economy as a whole and the people who depend upon them for support.

Then again, food stamp recipients didn’t donate $168,000 to Cantor’s reelection campaign in the last cycle. The drug industry did.

By: Jonathan Cohn, The New Republic, July 15, 2011

July 17, 2011 Posted by | Big Pharma, Budget, Businesses, Class Warfare, Congress, Conservatives, Corporations, Debt Crisis, Deficits, Democrats, Economic Recovery, Economy, GOP, Government, Government Shut Down, Health Reform, Ideologues, Ideology, Lawmakers, Medicaid, Medicare, Middle Class, Pharmaceutical Companies, Politics, Republicans, Right Wing, Seniors, Wealthy | , , , , , , , , , | Leave a comment

Republican Preachers: Believing What You Know Ain’t True

In Huckleberry Finn, Mark Twain makes a stinging observation on the overtly religious. “Faith is when you believe something you know ain’t true.” This is a perfect description of the religious asylum that is now the Republican Party and the tortured gospel they are spreading all over the country. Virtually the entire barnyard of their presidential candidates are preaching a mix of born again religious revivalism and brutal 19th century industrial capitalism, that they “know ain’t even remotely true.”

By and large these are not genetically stupid people. But the political trash talking they feel obligated to serve up to the Tea Party Gods–Rush Limbaugh and the inquisitors at Fox–has degenerated into a competition of who can do the best impression of an absolute lunatic. Rick Perry is preaching virtual secession from the union, while holding prayer vigils for God to solve our problems. By what twisted logic does contempt for the federal government and even secession equate to patriotism? Someone please show me where the founding fathers advocated prayer as the vehicle for solving a national debt crisis?

Mitt Romney and Tim Pawlenty have flip flopped on virtually every position they ever espoused so that their insanity titers can match Michelle Bachmann’s. I’ve met with Jon Huntsman on more than one occasion regarding environmental issues in Utah. He was a reasonable moderate Republican as my state’s governor and appeared on TV ads three years ago exhorting the entire country to act on the climate crisis. He did that because he respected the warnings of our climate scientists. Now he says we can’t deal with global warming in a depressed economy. He knows perfectly well that those same scientists are warning that if we don’t act on it right now, we condemn our children to a brutal, dangerous and likely unlivable world. Newt Gingrich? He appeared on national TV ads with Nancy Pelosi saying that he agreed on the urgency to deal with the climate crisis. Now he looks like a Keystone Cop, tripping over his own feet in full speed reverse.

Sarah Palin? Oh, never mind. Rick Santorum? According to him the world’s scientists are all in on a conspiracy with Al Gore. Really Rick? That conspiracy would have to have started in 1824 when the greenhouse gas phenomenon was first described by the French scientist Joseph Fourier. It would have to have involved scores of scientists in the 1800s like John Tyndall of the Royal Institute of Great Britain, George Marsh, the founder of the Smithsonian Institute, and hundreds of scientists in the 1900s like 1903 Nobel Prize winner Svante Arrhenius. The conspiracy would now have to involve virtually the entire world’s scientific community. That makes sense to you, Rick? Really?

Almost as irritating is the chorus sung over and over by Eric Cantor, John Boehner, Mitch McConnell, Paul Ryan and 99% of Republican Congressmen proudly declaring their Huckleberry Finn type faith that an unfettered free market is the only way to create to millions of new jobs. “Stop choking businesses with excessive regulations!” they chant. All businesses, all regulations. Really, Mitch? Never mind that it was precisely the elimination of, inadequacy of, or lack of enforcement of federal regulation that allowed Wall St. to drag the economy to the edge of the apocalypse and the very reason why there are no jobs. Never mind that it was poor regulation and free market cost cutting that brought us the Deep Water Horizon, Kalamazoo River, and now Yellowstone River oil spills. 1,800 oil spills have occurred in this country in the last five years totaling 16 million gallons of oil contaminating our land and water. And Mitt, you want regulators to get off the backs of the oil companies? Really?

Never mind that it was inadequate federal oversight and greedy, unfettered capitalism on steroids that allowed Massey Energy to commit manslaughter on 29 coal miners last year. Hey, Eric just what jobs are created by paring down our already bare bones federal food inspection? Will even more outbreaks of e-coli and salmonella in peanut butter, spinach, eggs, cantaloupe, sprouts and hamburger be counted as just collateral blessings from unleashing the free market? We certainly don’t want to pay for inspection of imported sea food from Japan because a little radioactivity in your tuna fish and scallops would probably just make it taste a little more crunchy.

Hey Newt, what jobs will be created by eviscerating the EPA and their enforcement of the Clean Air Act besides morticians and health care providers? Michelle, so you’re comfortable with eliminating money for bridge inspectors from the National Transportation Safety Board because the one that collapsed in your home state in 2007 only killed 13 people, and that’s a small price to pay for that warm, orgasmic tingle only the free market can give?

Lets certainly get regulators off the backs of the pharmaceutical industry because other than the millions of people who have been killed or injured by Phen-Fen, Vioxx, Avandia, Bextra, Cylert, Baycol, Palladone, Trasylol, Tylenol, Darvocet, Heparin and all the drugs now made with ingredients from China without any real standards or controls–i.e. most of them–there’s no reason to think an unregulated free market won’t work out just fine. Really, Sarah? So if defective and tainted drugs weed out the weak among us, that’s just the beauty of the Ayn Rand/Milton Friedman world view?

The entire middle class is struggling with unemployment, under employment, mounting debt, lost pensions, mortgages foreclosed or underwater, and you want to undo even the pathetic protections of the 2010 Consumer Protection Act and put Elizabeth Warren’s head on a platter? Really, Speaker Boehner? That’s the job elixir the middle class so desperately need?

As with most religions the Church of Unfettered Capitalism doesn’t have to make sense in order to thrive. But it does need preachers at the pulpit exhorting us to “believe in things that we know ain’t true” and the Republican Party can’t get enough of them. Huckleberry Finn would be so proud.

By: Brian Moench, CommonDreams.org, July 9, 2011

July 10, 2011 Posted by | Big Pharma, Capitalism, Class Warfare, Congress, Conservatives, Corporations, Debt Ceiling, Democracy, Economy, Energy, GOP, Government, Government Shut Down, Ideologues, Ideology, Jobs, Lawmakers, Middle Class, Politics, Republicans, Right Wing, Tea Party, Unemployed, Wall Street, Wealthy | , , , , , , , , , , , , , , , , , , , | Leave a comment

“We Hold These Truths To Be Self Evident”: Real Patriots Pay Taxes

Some of our nation’s biggest corporations are planning a tax holiday and they want you to pick up the tab.

Actually, you already pay for their routine tax avoidance through the use of tax havens in Bermuda, the Cayman Islands and elsewhere. These accounting acrobatics cost the U.S. Treasury $100 billion a year. Now they want Congress to pass a special tax holiday for money they “repatriate” back to the United States.

There’s nothing patriotic about this repatriation being pushed by Google, Cisco, Pfizer and other companies in the Win America campaign. To sell the tax holiday, they claim it will produce a burst of jobs and investment. In fact, Congress passed a “one-time-only” tax holiday in 2004 with similar promises. Instead, it produced a burst of shareholder dividends and stock buybacks, which goosed the pay of CEOs.

Corporations laid off workers and shifted even more income and investment to offshore tax havens in the wake of the 2004 tax holiday.

“Why should we reward firms for successfully gaming the tax system when we in turn are called on to make up the missing tax revenues?” Edward Kleinbard, former chief of staff of Congress’s Joint Committee on Taxation, told Bloomberg. “Much of these earnings overseas are reaped from an enormous shell game: Firms move their taxable income from the U.S. and other major economies — where their customers and key employees are in reality located — to tax havens.”

A favorite accounting trick is transferring a patent from the U.S. parent company to a subsidiary — often a shell company — in a tax haven. Profits from the patent go largely untaxed offshore while the costs of development, marketing and management remain in the U.S., where they are taken as tax deductions.

Pfizer was the largest beneficiary of the last tax holiday, bringing $37 billion back to the United States and paying just $1.7 billion in federal corporate income taxes. It laid off 10,000 American workers in the following months. The U.S. is the world’s most profitable drug market and yet over the last three years, Pfizer — maker of Lipitor, Viagra and much more — has reported $7.9 billion in U.S. losses while claiming $37.8 billion in profits in the rest of the world. Pfizer, like the rest of Big Pharma, is heavily subsidized by taxpayer-funded research at the National Institutes of Health and elsewhere. It should not be rewarded with another tax holiday.

Bloomberg reported that “Google reduced its income taxes by $3.1 billion over three years by shifting income to Ireland, then the Netherlands, and ultimately to Bermuda.” What a corporate ingrate. Google would not exist without the Internet, and the Internet grew out of U.S. government research beginning in the 1960s. In the 1990s, the U.S. National Science Foundation funded the Digital Library Initiative research at Stanford University that Larry Page and Sergey Brin, now billionaires, developed into Google. Brin was also supported by an NSF graduate student fellowship.

Increasingly, U.S. multinational corporations want to benefit from government spending on education, infrastructure, research, health care and so on without paying for it. Today, large corporations pay, on average, 18 percent of their profits in federal income taxes and as a group contribute just 9 percent toward federal government bills, down from 32 percent in 1952. The Congressional Joint Committee on Taxation says a new tax holiday would cost $79 billion.

A dozen national and state business organizations led by Business for Shared Prosperity recently wrote members of Congress urging them to oppose the tax holiday. The letter said, “When powerful large U.S. corporations avoid their fair share of taxes, they undermine U.S. competitiveness, contribute to the national debt and shift more of the tax burden to domestic businesses, especially small businesses that create most of the new jobs.”

There is no excuse for repeating a policy that’s a proven failure. It would be even worse this time around, as corporations would redouble their efforts to shift profits overseas in anticipation of the next tax holiday. Congress should close the tax loopholes that reward companies for transferring U.S. profits, jobs and investment abroad — not encourage them.

Real patriots pay their fair share of taxes. They don’t run out on the bill.

 

By: Holly Sklar and Scott Klinger, CommonDreams.org, July 4, 2011

July 4, 2011 Posted by | Big Business, Big Pharma, Capitalism, Class Warfare, Congress, Conservatives, Corporations, Deficits, Democracy, Economic Recovery, Economy, GOP, Government, Jobs, Lawmakers, Middle Class, Offshore Accounts, Politics, Republicans, Tax Evasion, Tax Liabilities, Tax Loopholes, Taxes, Wealthy | , , , , , , , , , , | Leave a comment

Drug Marketing and Free Speech: U. S. Supreme Court Says Data Mining Trumps Your Medical Privacy

Pharmaceutical companies, which spend billions of dollars a year promoting their products to doctors, have found that it is very useful to know what drugs a doctor has prescribed in the past. Many use data collected from prescriptionsprocessed by pharmacies — a doctor’s name, the drugs and the dosage — to refine their marketing practices and increase sales.

The Supreme Court on Thursday made it harder for states to protect medical privacy with laws that regulate such practices. In 2007, Vermont passed a law that forbade the sale of such records by pharmacies and their use for marketing purposes. The ruling upheld a lower court decision that struck down the law as unconstitutional.

Justice Anthony Kennedy, writing for the 6-to-3 majority, said the law violates First Amendment rights by imposing a “burden on protected expression” on specific speakers (drug marketers) and specific speech (information about the doctors and what they prescribed). It is unconstitutional because it restricts the transfer of that information and what the marketers have to say.

In dissent, Justice Stephen Breyer explains that the law’s only restriction is on access to data “that could help pharmaceutical companies create better sales messages.” He notes that any speech-related effects are “indirect, incidental, and entirely commercial.” By applying strict First Amendment scrutiny to this ordinary economic regulation, he warns, the court threatens to substitute “judicial for democratic decision-making.”

The law would have been upheld, Justice Breyer says, if the court had treated it as a restriction on commercial speech, which is less robustly protected than political speech. The court’s majority unwisely narrows the gap between commercial and political speech, and makes it harder to protect consumers.

By:  Editorial, The New York Times, June 23, 2011

June 24, 2011 Posted by | Big Pharma, Constitution, Consumers, Corporations, Democracy, Freedom, Pharmaceutical Companies, Politics, Regulations, Supreme Court | , , , , , , , , , , , , , , , | Leave a comment

Drugs and Profits: Pharmaceutical Companies Should First Do No Harm

Last year the Food and Drug Administration rescinded approval of the drug Avastin for treating breast cancer patients, prompting a firestorm of criticism. The decision was denounced by some politicians as health care rationing, and by breast cancer patients who feared that they would be deprived of a drug that they felt had helped them immensely.

But these criticisms ignore the facts: Avastin was rejected simply because it didn’t work as it was supposed to, and the F.D.A. should resist the aggressive campaign by Genentech, the drug’s maker, to get that ruling reconsidered at a hearing in late June.

Avastin has been on the market for seven years, and combined with other drugs it is effective in treating, but not curing, some colon, lung, kidney and brain cancers. It inhibits the development of new blood vessels and in so doing can starve a growing tumor.

Treating a breast cancer patient with Avastin costs about $90,000 a year, and Genentech could lose $500 million to $1 billion a year in revenue if the F.D.A. upholds the ban.

A clinical trial published in 2007 demonstrated that Avastin, when paired with the chemotherapy drug Taxol, halts the growth of metastatic breast cancer for about six months longer than chemotherapy alone. Genentech then asked the F.D.A. for approval of Avastin, combined with Taxol, for use against metastatic breast cancer.

This halt in tumor growth is known as progression-free survival. But delaying the worsening of cancer does not necessarily prolong life, and Avastin was not shown to lengthen patients’ overall survival time. So Genentech argued that the drug led not to longer life, but to improved quality of life.

In 2007, an F.D.A. advisory committee rejected the application, deciding that the toxic side effects of Avastin outweighed its ability to slow tumor growth. The F.D.A., however, overrode the committee and granted what is called accelerated approval, allowing Avastin to be used pending further study. The criteria for full approval was that Avastin not worsen overall survival and that the drug provide clinically meaningful progression-free survival.

To support its case Genentech submitted data from two additional clinical trials in which Avastin was paired with chemotherapy drugs other than Taxol. Like the first trial, neither showed a survival benefit. Both showed an improvement in progression-free survival, though this outcome was much less impressive than in the original study. In addition to seeking full approval for the Avastin-Taxol combination, Genentech also asked the F.D.A. to approve the use of Avastin with the drugs used in these follow-up studies.

Genentech presented progression-free survival as a surrogate for better quality of life, but the quality-of-life data were incomplete, sketchy and, in some cases, non-existent. The best that one Genentech spokesman could say was that “health-related quality of life was not worsened when Avastin was added.” Patients didn’t live longer, and they didn’t live better.

It was this lack of demonstrated clinical benefit, combined with the potentially severe side effects of the drug, that led the F.D.A. last year to reject the use of Avastin with Taxol or with the other chemotherapies for breast cancer.

In its appeal Genentech is changing its interpretation of its own data to pursue the case. Last year Genentech argued that the decrease in progression-free survival in its supplementary studies was not due to the pairing of Avastin with drugs other than Taxol. This year, however, in its brief supporting the appeal, Genentech argues that the degree of benefit may indeed vary with “the particular chemotherapy used with Avastin.” In other words, different chemotherapies suddenly do yield different results, with Taxol being superior. The same data now generate the opposite conclusion.

Perhaps more troubling is the resort to anecdote in the brief to the F.D.A. and in the news media.  Oncologists recounted their successes, and patients who were doing well on Avastin argued for its continued approval. But anecdote is not science. Such testimonials may represent the human voices behind the statistics, but the sad fact is that there are too many patients who have been treated with Avastin but are not here to tell their stories.

Avastin will not disappear because of the F.D.A. decision. It remains available for treating other cancers, and research to find its appropriate role in breast cancer treatment continues. In the meantime, the F.D.A., which is expected to make its decision in September, needs to resist Genentech’s attempt to have it ignore scientific evidence.

Serious progress in the treatment of cancer will not be the result of polemics, lobbying or marketing. Genentech’s money and efforts would be better spent on research for more meaningful treatments for breast cancer.

By: Frederick C. Tucker, Jr., Oncologist and Op Ed Contributor, The New York Times Opinion Pages, May 24, 2011

May 25, 2011 Posted by | Big Pharma, Capitalism, Consumers, Corporations, Government, Health Care, Health Care Costs, Health Reform, Pharmaceutical Companies, Politics, Public Health, Regulations, U.S. Chamber of Commerce, Women, Women's Health, Womens Rights | , , , , , , , , , , , , , , , , , | Leave a comment